Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillation

Abstract

AimsCardiac functional and structural remodelling in patients with atrial fibrillation (AF) contributes to development of heart failure (HF) as their major cardiovascular comorbidity. Circulating biomarkers may reflect these cardiac alterations.Methods and resultsENGAGE AF‐TIMI 48 was a randomized trial of edoxaban versus warfarin in 21 105 patients with AF. We performed a nested biomarker study, analysing high‐sensitivity troponin T (hsTnT, n = 8705), N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP, n = 8765), and growth differentiation factor‐15 (GDF‐15, n = 8705) at baseline and 12 months. Of the biomarker cohort, 5207 had a history of HF, among whom 3996 had known ejection fraction (EF): 926 with reduced EF (HFrEF; ≤40%), 1043 with mildly reduced EF (HFmrEF; 40–49%), and 2027 with preserved EF (HFpEF; ≥50%). Elevated baseline hsTnT, NT‐proBNP, and GDF‐15 were associated with higher risk of hospitalization for HF (HHF) or HF death overall and in subpopulations defined by HF history and EF (p < 0.001 for each). These associations of outcome with each biomarker were consistent regardless of a history of HF or EF (p‐interaction >0.05 for each). Patients who had an increase in or had persistently elevated values in any of the three biomarkers over 12 months were at higher risk for HHF or HF death in the overall population (p < 0.001 for each biomarker and category).ConclusionSerial measurement of hsTnT, NT‐proBNP, and GDF‐15 revealed that higher baseline values, and increasing or persistently elevated values over 1 year are associated with higher risk of HF outcomes in patients with AF regardless of HF history or HF phenotype based on EF.Clinical Trial Registration: ClinicalTrials.gov unique identifier NCT00781391.